Abstract:Mesenchymal Stem Cells/Multipotent Marrow Stromal Cells (MSC) are multipotent adult stem cells harboring a wide range of differentiation capacities as well as non‐HLA restricted immunosuppressive properties, leading to an increase in their uses for immunomodulation and regenerative medicine. MSC are generally cultivated from bone marrow (BM). Alternative sources (e.g. adipose tissue or umbilical cord) are rapidly developing. Considering the starting material used, the differentiation potential may be different, in example adipose tissue derived MSC exhibit a greater potential for endothelium repair. Whatever the sources of MSC, a first step of adherence to plastic is required. When seeding, the cell density is of major importance acting on growth speed, cell amplification, and differentiation potential. Considering medium used, until now serum free media are not available to cultivate MSC for clinical application. Standard process with FCS without any growth factor supplementation is effective but time consuming, sometime failing, and not totally secure. Although processes using recombinant growth factors (e.g. FGF2) or platelet lysate have demonstrated their interest, definitive standards to produce clinical‐grade MSC are still lacking. To reach GMP standards, two major steps have to be done. First, MSC cultures need to be done in closed system; this step is not easy to perform. Second, the controls of produced batches have to ensure efficacy and safety. Now, the controls are principally based on FACS analysis and the expected CD73 pos CD105 pos CD90 pos CD45 neg MSC phenotype is easily obtained. But the major problem remains the lack of fully validated controls of the final cell product efficacy and safety. Considering the genetic stability of MSC during culture processes, whatever the culture method, aneuploidy could occur during clinical‐grade production of BM‐MSC but does not lead to cell transformation. But these results should lead to develop more accurate and powerful controls of all MSC in cultures.

Considerations of Quality Control Issues for the Mesenchymal Stem Cells-Based Medicinal Products

Quality Control Optimization for Minimizing Security Risks Associated with Mesenchymal Stromal Cell-Based Product Development

Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges

The quality evaluation system establishment of mesenchymal stromal cells for cell-based therapy products

Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China Version)

Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: Promises, problems and prospects

Metabolic Regulation of Mesenchymal Stem Cell in Expansion and Therapeutic Application

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

Challenges and Controversies in Human Mesenchymal Stem Cell Therapy

Mesenchymal stem cells biological and biotechnological advances: Implications for clinical applications

Mesenchymal Stem Cells: Molecular Characteristics and Clinical Applications

MSCs: Biological Characteristics, Clinical Applications and Their Outstanding Concerns

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges

Mesenchymal stem cells: Cell therapy and regeneration potential

Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine

Generation and characterization of mesenchymal stromal cells for clinical application

Challenges and Clinical Therapeutic Options

Improved Therapeutics of Modified Mesenchymal Stem Cells: an Update

Controversies regarding transplantation of mesenchymal stem cells

The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy